SFDA To Reappraise Safety Of TCM Injections
This article was originally published in PharmAsia News
Executive Summary
China's State FDA stated on its official website that the agency will soon start reappraising the safety of TCM injections nationwide in order to raise safety and quality standards and eliminate medicines with potential safety issues. SFDA has drawn up separate drafts on the key points of quality control and the primary requirements for TCM injection safety reappraisal. The documents are currently open to public feedback. TCM injection producers should actively conduct inspections to remove potential hazards in production and take measures to control risks. In addition, SFDA will carry out a survey of TCM injections' quality control. (Click here for more - Chinese Language)